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Highlights 14 
• Protective immunity against malaria can be achieved through immunisation with live 15 
attenuated Plasmodium sporozoites and targets the parasite pre-erythrocytic stages. 16 
• Naturally exposed individuals remain at risk of malaria despite multiple sporozoite 17 
infections, and this could be explained by different mechanisms. 18 
• Protective immunity relies primarily on effector CD8+ T cells targeting the parasite in 19 
the liver. 20 
• The generation of liver-resident parasite-specific memory CD8+ T cells is emerging as 21 
a key determinant of protective immunity. 22 
 23 
 24 
 25 
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Abstract 26 
Complete and long-lasting protective immunity against malaria can be achieved through 27 
vaccination with invasive live attenuated Plasmodium sporozoites, the motile stage inoculated 28 
in the host skin during a mosquito bite. Protective immunity relies primarily on effector CD8+ 29 
T cells targeting the parasite in the liver. Understanding the tissue-specific features of the 30 
immune response is emerging as a vital requirement for understanding protective immunity. 31 
The small parasite inoculum, the scarcity of infected cells and the tolerogenic properties of 32 
the liver represent hurdles for the establishment of protective immunity in endemic areas. In 33 
this review, we discuss recent advances on liver-specific features of immunity including 34 
innate recognition of malaria pre-erythrocytic stages, CD8+ T cell interactions with infected 35 
hepatocytes, antigen presentation for effective CD8+ T cell responses and generation of liver-36 
resident memory CD8+ T cells. A better understanding of the factors involved in the induction 37 
and maintenance of effector CD8+ T cell immunity against malaria pre-erythrocytic stages is 38 
crucial for the development of an effective vaccine targeting the initial phase of malaria 39 
infection. 40 
 41 
  42 
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Introduction 43 
Malaria, caused by Plasmodium parasites, is one of the leading causes of mortality and 44 
morbidity in resource poor areas worldwide. Notwithstanding global control and elimination 45 
efforts, >400,000 people still die annually due to malaria 46 
(http://www.who.int/malaria/publications/world-malaria-report-2016/report/en). A highly 47 
efficacious malaria vaccine remains elusive. Plasmodium sporozoites are injected in the host 48 
skin by a female infected Anopheles mosquito. These sporozoites travel to the liver, invade 49 
hepatocytes and develop into exo-erythrocytic forms (EEF), which generate thousands of 50 
blood stage parasites. Targeting the malaria pre-erythrocytic stage is an ideal and attractive 51 
strategy for malaria vaccination. Inhibiting liver infection and development of malaria 52 
parasites can prevent both the disease-causing blood stages and the transmissible sexual 53 
stages. 54 
Humans, rhesus monkeys and mice exposed to multiple doses of g-radiation-attenuated 55 
sporozoites (RAS), the gold standard vaccine for malaria, can be fully protected against 56 
normal sporozoite challenge (reviewed in [1]). Alternative attenuation strategies, such as 57 
genetically attenuated parasites (GAP) or chemoprophylaxis with sporozoite infection (CPS), 58 
also induce sterile protection (reviewed in [2]). Whilst the use of attenuated parasites is a 59 
feasible approach for vaccination, they demand production of large quantities of infected 60 
mosquitoes that is not easily scalable to mass vaccination in poor settings. But, if we can 61 
discover the important features of a protective immune response, we can replicate these 62 
phenotypes by sub-unit vaccination. RTS,S/AS01, the most advanced malaria sub-unit 63 
vaccine candidate to date, is based on the circumsporozoite protein (CSP), the surface coat 64 
antigen of sporozoites. Yet, despite being designed to elicit different arms of the immune 65 
response, RTS,S/AS01 only provides partial protection in malaria-naïve and –experienced 66 
individuals [3•]. 67 
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In rodent models and rhesus monkeys, protection conferred by RAS vaccination is 68 
largely dependent on effector CD8+ T cells (reviewed in [4]). Depletion of CD8+ T cells prior 69 
to challenge of immunised mice and rhesus monkeys consistently abrogated protection [5,6]. 70 
P. falciparum (Pf) RAS vaccination of humans induces high numbers of sporozoite-specific 71 
CD8+ T cells producing IFN-g [7]. Understanding the key features of host-parasite 72 
interactions and the induction of innate and adaptive immune responses, particularly parasite-73 
specific CD8+ T cells, is crucial for informing the development of an effective next generation 74 
malaria vaccine. 75 
 76 
Immunisation with attenuated parasites versus natural infections: numbers matter 77 
Despite repeated infections, individuals in endemic areas do not develop sterilising 78 
protection and those surviving episodes of childhood malaria remain vulnerable to 79 
intermittent infections [8]. Several possibilities, including the small number of parasites 80 
naturally transmitted by mosquitoes or the down-regulation of immunity by malaria blood 81 
infection, can explain the reasons behind the contrasting outcomes with those experimentally 82 
vaccinated with attenuated sporozoites (Figure 1). 83 
In mice, only ~20-50 P. yoelii (Py) or P. berghei (Pb) sporozoites are inoculated in the 84 
host skin during an infective bite and only a small fraction invades and develops inside 85 
hepatocytes (reviewed in [9]). CD8+ T cell responses to CSP and sporozoites following Py 86 
and Pf RAS immunisation, respectively, are dependent on antigen dose so low inoculum 87 
equates to poor CD8+ T cell responses [7,10]. In the Py model, CD8+ T cell responses are not 88 
readily increased by repeated immunisation [11,12]. To achieve sterile protection in humans, 89 
more than 1,000 Pf infective bites (Pf RAS) are required [13]; this  amount corresponds to 90 
almost ten years of exposure to Pf in a high malaria transmission area [14] but administered in 91 
a much shorter period. Sterile protection can also be achieved by the intravenous inoculation 92 
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of ~700,000 Pf RAS [7]. To protect humans under CPS, fewer Pf infective bites (~40) or 93 
cryopreserved sporozoites (~150,000) are needed [15,16•]. For CPS, the host is exposed to 94 
both pre-erythrocytic and blood stage (transient parasitemia) antigens, and sterile protection is 95 
observed only against a Pf sporozoite challenge [17]. Comparable to findings in humans, CPS 96 
induces efficient protection against Pb sporozoite infection, but not against blood stage 97 
challenge. This sterilising protection is abolished after depletion of CD8+ T cells and is not 98 
affected by the lack of mature B cells [18,19]. In contrast, CPS vaccination not only induces 99 
high levels of antigen-experienced CD8+ T cells but also targets blood stages of Py and P. 100 
chabaudi (Pc) [18,20–22]. In common, the two species used in these studies cause an acute 101 
parasitemia that can be naturally controlled by non-vaccinated hosts, indicating a lower 102 
stringency for the immune-control of the blood stage infection in comparison to the Pb and Pf 103 
lethal strains. Late arresting Py GAPs have been shown to provide superior protective 104 
immunity, suggesting a role of mid/late EEFs antigens in protection, and similar to RAS and 105 
CPS, sterile protection is dependent on the immunising dose of attenuated sporozoites [23]. 106 
These data suggest that exposure to a broad antigenic repertoire, including antigens shared 107 
between EEFs and blood stages, improves protection against the pre-erythrocytic stages. 108 
Additionally, the absence or the rapid clearance of infected RBCs by RAS/GAP or CPS 109 
vaccination, respectively, might impede the deleterious effect of blood infection on antigen 110 
presentation [24], the numbers and functionality of CD8+ T cells [25] or the expansion of 111 
regulatory T cells during a prolonged blood-infection [26•]. Overall, the delivery of high 112 
doses of sporozoites seems to be a key requirement for the sterile protection elicited by 113 
immunization using live attenuated sporozoites. This high antigenic load is likely associated 114 
with overcoming the humoral and cellular effector thresholds necessary to sterilize the 115 
sporozoite infection [27,28]. 116 
 117 
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Early responses to sporozoites and liver stages: innate immunity and hepatic responses 118 
Information on how sporozoites interact with the innate immune system remains 119 
limited. Pb sporozoites induce the biphasic recruitment of CD11b+ Ly6Cint Ly6Ghi 120 
polymorphonuclear neutrophils, CD11b+ Ly6C− Ly6G− resident myeloid cells and CD11b+ 121 
Ly6Chi Ly6G− inflammatory monocytes in the skin inoculation site and the proximal draining 122 
lymph node (DLN), evoking a Th1 cytokine profile [29]. Migrating Pb sporozoites induce a 123 
signalling cascade in vitro in primary murine hepatocytes with MyD88-mediated NF-KB 124 
activation [30]. Although EEF development is clinically silent, accumulating evidence 125 
suggest that, as parasites replicate in the liver, functional innate immune responses are 126 
triggered that are dependent on both type I and II IFNs [31•,32•]. The type I IFN signaling 127 
pathway is activated in the livers of mice intravenously infected with either Pb or Py, a 128 
process that involves the cytosolic receptor melanoma differentiation-associated protein 5 129 
(Mda5), suggesting sensing of parasite RNA, and requires the mitochondrial antiviral 130 
signalling protein (Mavs) and the transcription factors interferon-regulatory factors-3 (Irf3) 131 
and Irf7. Type I IFNs bind to Ifnar on hepatocytes and leukocytes, resulting in the subsequent 132 
recruitment of leukocytes to the liver at the end of the hepatic infection. Indeed, following the 133 
inoculation of Py GAP, type I IFN signalling is essential for the recruitment or expansion of 134 
CD49b+CD3+ Natural Killer T (NKT) cells, one day after the peak of hepatic parasite release 135 
in the blood circulation. These NKT cells reduce liver infection during a subsequent and 136 
intertwined secondary Py sporozoite infection, presumably via the production of IFN-g [32•]. 137 
However, type I IFN signalling does not impact the EEF growth after a primary Pb or Py 138 
sporozoite infection [31•,32•]. Furthermore, earlier reports using Pb and Py suggest that NKT 139 
cells have no role in protection against malaria pre-erythrocytic stages [33,34]. Notably, a 140 
type I IFN response of much lower magnitude was observed when lower doses of parasites 141 
were transmitted through mosquito bites [31•]. Hence, the significance of this response and its 142 
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relevance in humans still remains uncertain, as well as its impact on the acquisition of 143 
immunity by vaccination using live attenuated sporozoites. During EEF development, the 144 
parasite exploits diverse cellular pathways and several host and immune factors are 145 
modulated, including Bcl-2, p53, IL-6, heme oxygenase and the autophagy machinery 146 
(reviewed in [35,36] and [37]). The relationships amongst the modulation of host cell factors, 147 
the innate immune system and the development of protective CD8+ T cells against pre-148 
erythrocytic stages remain to be established. 149 
 150 
Antigen capture and presentation leading to CD8+ T cell priming 151 
How parasite antigens are processed and presented for primary activation of antigen-specific 152 
CD8+ T cells is not well understood, but likely depends on the nature and spatio-temporal 153 
exposure of parasite-derived antigens. Sporozoites migrate through various cell types during 154 
their journey from the skin to the liver. During cell traversal, sporozoites shed antigens in the 155 
host cell cytosol, which can be processed and directly presented [38] or captured for cross-156 
presentation by dendritic cells (DCs). After dermal inoculation, a fraction of Pb sporozoites 157 
actively migrate to the DLN [39], and can prime protective PyCSP-specific CD8+ T cells [40]. 158 
Lymph-node resident CD8α+ DCs capture antigens from migratory malaria sporozoites and 159 
induce PbCSP-specific CD8+ T cell responses [41]. Intravenous inoculation of live attenuated 160 
sporozoites is a more efficient vaccination approach as compared to intradermal inoculation, 161 
in both human and rodents models [7,42]. Various factors likely concur to protective 162 
immunity induced by immunization with live attenuated sporozoites administered 163 
intravenously (Figure 2). A recent study revealed that the lower protective efficacy of Py 164 
GAP administered via the intradermal route is not linked to low hepatic parasite numbers, but 165 
correlates with a shift towards regulatory immune responses [43•]. In particular, more 166 
interleukin-10-producing B and T cells but fewer hepatic memory CD8+ T cells and CD8a+ 167 
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DCs were found in the liver and skin DLNs after intradermal injection, as compared to 168 
intravenous inoculation. Intravenous injection of Pb RAS leads to a CD8a+ DC-dependent 169 
splenic priming of CD8+ T cells specific for an antigen expressed in pre-erythrocytic and 170 
blood stages [44]. CD8α+ DCs accumulate in the liver after Pb RAS immunisation [45,46], 171 
however a role for hepatic DCs in both priming of CD8+ T cells and protection remains poorly 172 
characterised. In the liver, sporozoites traverse Kupffer cells (KC) and liver sinusoidal 173 
endothelial cells (LSEC) prior to infecting hepatocytes [47]. In other systems, both KC and 174 
LSEC can function as APCs and could present parasite antigens to CD8+ T cells, resulting in 175 
either tolerance or enhanced immune responses in inflammatory conditions [48,49]. 176 
How antigens expressed exclusively during EEF development are presented to the 177 
immune system is unclear. After invasion of hepatocytes, Plasmodium parasites replicate 178 
within the PV membrane (PVM), which constitutes a barrier preventing access of antigens to 179 
the host cell cytosol and the MHC class I presentation pathway. RAS and GAP invade 180 
hepatocytes where they undergo arrested development into EEFs. Attenuation leads to 181 
parasite death and possible breakdown of the PVM, which could also enhance antigen 182 
presentation and priming of protective CD8+ T cells. Although antigen presentation by 183 
hepatocytes tends to have a tolerising effect (reviewed in [50]), hepatocytes were shown to 184 
prime CD8+ T cells specific for CSP [51]. Furthermore, a recent study revealed that 185 
presentation of antigens expressed in hepatocytes leads to differentiation of systemically 186 
primed CD8+ T cells into liver-resident memory cells that are critical for protection [52••]. 187 
During the effector phase of an efficient immune response, protective CD8+ T cells 188 
recognize parasite-derived peptides displayed with MHC class I molecules on the surface of 189 
infected hepatocytes, leading to parasite elimination [40,53,54]. In Py-infected hepatocytes, 190 
antigen processing and presentation follows an endosomal-independent, TAP-dependent 191 
pathway [53,55] requiring an intracellular source of parasite antigens. From thousands of 192 
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proteins expressed by sporozoites and liver-stages, so far, only a few antigens, conserved 193 
among plasmodial species, are known to elicit a CD8+ T cell-dependent protection against a 194 
sporozoite infection. Among them are the two most abundant surface proteins of sporozoites, 195 
CSP [56] and the thrombospondin-related anonymous protein (TRAP/SSP2) [57]; a protein 196 
involved in the wounding and traversal of host cells by ookinetes and sporozoites (CelTOS) 197 
[58]; an asparagine-rich protein that regulates the initial development of liver stages (SLARP/ 198 
SAP1) and a putative serine hydroximethytransferase (SHMT) [59]. Pf liver-stage antigen 1, 199 
liver-stage associated protein 2 and UIS3 antigens also elicit CD8+ T cell-dependent 200 
protection in a challenge model where heterologous Pb sporozoites over-express these 201 
antigens via the strong uis4 promoter [60,61]. The expression of the OVA MHC-I epitope 202 
fused to the HSP70 or the green fluorescent protein in the parasite cytosol via the constitutive 203 
hsp70 promoter can also lead to the elimination of infected hepatocytes by OVA-specific 204 
CD8+ T cells [53], showing that cytosolic, membrane, secreted and PVM antigens can be 205 
potentially presented on the surface of infected hepatocytes. 206 
 207 
Effector functions of protective CD8+ T cells 208 
Different effector molecules can be utilised by both effector and memory CD8+ T cells 209 
to protect against infections, including IFN-g, tumour necrosis factor (TNF), perforin, 210 
granzyme, FasL and TNF-related apoptosis-inducing ligand (TRAIL). The mechanisms by 211 
which CD8+ T cells inhibit the development of pre-erythrocytic stages remain poorly 212 
understood. Studies using antigenically distinct Pb strains showed that bystander killing of 213 
parasites does not occur during the CD8+ T cell response to malaria parasites [62], indicating 214 
that elimination of infected parasites is likely mediated by direct recognition of infected 215 
hepatocytes by antigen-specific CD8+ T cells. Systemic depletion of IFN-g which is produced 216 
not only by CD8+ T cells but also by CD4+ T, NK T and NK cells, consistently abolishes 217 
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sterile protection in rodent models immunised with Pb or Py RAS [5]; IFN-g activates the L-218 
arginine-dependent inducible nitric oxide synthase (iNOS) pathway, which leads to the 219 
production of nitric oxide (NO) that is toxic to the developing EEFs (reviewed in [1]). Lytic 220 
factors appear to be dispensable in the effector function of CD8+ T cells against pre-221 
erythrocytic stages. Mice deficient for perforin, granzyme B or FasL and immunised with 222 
either Pb or Py RAS are completely protected against sporozoite challenge [5,63]. However, 223 
the roles for other immune mechanisms were not properly studied in these gene-deficient 224 
animals. Several experiments have also been performed using peptide-stimulated activated 225 
CD8+ T cells or vaccine-induced CD8+ T cells. Activated CD8+ T cells specific for a 226 
cytoplasmic antigen in EEFs and generated by peptide-stimulation were shown to eliminate 227 
developing parasites in the liver in the absence of IFN-g [53]. Effector PyCSP-specific CD8+ 228 
T cells that are deficient of perforin, granzyme B or FasL, and generated following 229 
vaccination with recombinant vaccinia virus, were capable of targeting the developing EEFs 230 
[64]. Finally, an immunisation strategy involving priming with DCs and boosting with 231 
recombinant Listeria monocytogenes to generate memory PbCSP- or PyCSP-specific memory 232 
cells showed the importance of both IFN-g and TNF in protection against Pb and Py, whilst 233 
perforin was only involved in protection against Py, providing evidence of species-specific 234 
effector mechanisms for parasite killing [65]. 235 
Live cell imaging was utilised to dissect the fine mechanisms of CD8+ T cell 236 
recognition of infected hepatocytes. Polyclonal CD8+ T cells from mice immunised with Py 237 
GAP were shown to establish immunological synapses in vitro and utilise perforin to induce 238 
massive apoptosis of infected hepatocytes, with no detectable production of IFN-g and TNF 239 
[66]. Intravital imaging revealed that PyCSP-specific effector CD8+ T cells (generated by 240 
peptide-stimulation or a recombinant viral vaccination), as well as non-specific CD8+ T cells, 241 
form clusters around infected hepatocytes, a process requiring G protein-coupled receptors 242 
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[53,67]. Targeting by PyCSP-specific effector CD8+ T cells showed heterogeneity in the death 243 
phenotypes of the parasite, implying that multiple and redundant mechanisms are involved 244 
[67]. Taken together, these findings uphold the view that elimination of infected hepatocytes 245 
occurs in a multifaceted process. 246 
 247 
The role of liver-resident memory CD8+ T cells in protective immunity 248 
To induce sterilising immunity against EEFs, CD8+ resident or recruited to the liver 249 
must locate and eliminate all parasites to prevent progression to the blood stage infection [62], 250 
in a limited amount of time (2 days in mouse, 7-10 days in humans). CD8+ T cells must find 251 
rare events: estimated at 1 out of 109 hepatocytes in humans and 1 out of 106 hepatocytes in 252 
mice [4]. Consequently, extremely high numbers of circulating vaccine-induced effector 253 
CD8+ T cells are required to scan, locate and kill infected hepatocytes in the short amount of 254 
time the parasites are in the liver [28,68]. 255 
Accumulating evidence indicates a vital role for liver-resident CD8+ T cells in 256 
protective immunity to pre-erythrocytic stages. Long-term protection after immunisation with 257 
Pb RAS and CPS correlates with sustained IFN-γ responses of hepatic CD8+ memory T cells 258 
[69]. Recent studies in non-human primates have also correlated liver CD8+ T cell numbers 259 
with protective efficacy after intravenous RAS vaccination [70•]. Memory PyCSP-specific 260 
CD8+ T cells express high levels of CXCR6 [71]. Poor CXCR6 expression in these cells 261 
results in a reduction of both liver-associated memory and protective immunity [72], 262 
suggesting a role of resident CD8+ T cells in protection. Intravital imaging documented the 263 
presence of motile CD8+ T cells within the liver sinusoids of Py RAS vaccinated mice, 264 
suggesting that memory T cells survey for liver infection by patrolling the sinusoids [73]. 265 
More recently, a study based on transgenic CD8+ T cells specific for a Pb antigen expressed 266 
in pre-erythrocytic and blood stages, identified a population of memory CD8+ T cells in the 267 
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liver that express a distinct phenotype (CD69+ KLRG1lo) from splenic memory cells that are 268 
CD69- KLRG1hi [52••]. Detailed phenotypic analysis revealed that liver Trm cells also lacked 269 
CD103 expression and differentially expressed a number of surface markers, with higher 270 
levels of CXCR3, CXCR6, CD101, BTLA, FR4, Ly6ae, CD25, CD31, CD93, IL-4R, CD127, 271 
gp130, CD200R, and CD43, but lower levels of CX3CR1 and NKG2D as compared to 272 
circulating effector memory T cells [52••]. Induced following Pb RAS immunisation, these 273 
tissue-resident memory T (Trm) cells have the core gene signature of Trm cells from gut, skin 274 
and lung. Parabiosis experiments in mice showed that these cells do not recirculate, 275 
confirming their liver-resident status [52••]. Intravital imaging revealed that liver-resident 276 
cells depend on LFA-ICAM-1 interactions [74]. An immunisation strategy, which involves 277 
systemic DC-targeted priming followed by the expression of the antigen on hepatocytes to 278 
trap circulating primed CD8+ T cells in the liver, enabled conversion to Trm cells [52••]. In 279 
this study, DC-targeted priming was achieved by conjugating the peptide antigen to a 280 
monoclonal antibody that targets the surface receptor Clec9A, which is expressed by CD8a+ 281 
DCs, and a recombinant adeno-associated virus that targets hepatocytes was used to express 282 
the antigen in the liver. This prime-trap vaccination strategy was shown to protect against 283 
normal Pb sporozoite challenge [52••]. 284 
 285 
Conclusion 286 
Despite the strong evidence for the role of CD8+ T cells in sterile protection against 287 
malaria, critical qualitative and quantitative characteristics of the protective response and 288 
effector mechanisms engaged by CD8+ T cells have only started to emerge recently. Whilst 289 
multiple immune mechanisms appear to contribute to protection against pre-erythrocytic 290 
stages, the generation of liver-resident parasite-specific memory CD8+ T cells is emerging as 291 
a key determinant of protective immunity. The design of strategies inducing this type of 292 
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response and the identification of protective target antigens will be instrumental for the 293 
development of an efficacious malaria vaccine. 294 
 295 
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Figure legends 575 
Figure 1. Potential factors contributing to the lack of protective immunity during 576 
natural Plasmodium infection. Under natural transmission conditions, only a few 577 
sporozoites are injected by an infected mosquito into the host skin. The motile sporozoites 578 
enter the blood stream by traversing a dermal capillary, are transported to the liver and 579 
traverse across liver sinusoidal endothelial cells (LSEC) or Kupffer cells (KC) to reach 580 
hepatocytes. Sporozoites invade hepatocytes inside a vacuole, where they replicate into 581 
thousands of merozoites, which once released into the bloodstream invade erythrocytes and 582 
initiate the blood stage infection. A combination of factors concurs to the lack of protective 583 
immunity in naturally exposed individuals. Infected mosquitoes inject very low numbers of 584 
sporozoites (1). Dermal inoculation is associated with immune regulatory mechanisms (2). 585 
The liver environment is prone to immune tolerance (3). The membrane of the 586 
parasitophorous vacuole limits diffusion of parasite liver stage antigens and exposure to the 587 
immune system (4). The blood stage infection that follows complete parasite development in 588 
the liver has immunosuppressive effects on liver stage immunity (5). 589 
 590 
Figure 2. Potential factors contributing to protective immunity against liver stages after 591 
immunisation with live attenuated sporozoites administered intravenously. Immunisation 592 
with live attenuated sporozoites administered intravenously is the most efficient approach to 593 
confer full protection against normal sporozoite challenge. Under these conditions, high 594 
numbers of sporozoites can be inoculated (1), allowing systemic delivery of antigens (2). 595 
Alteration of the parasitophorous vacuole integrity in arrested liver stage parasites likely 596 
favours exposure of liver stage antigens to the immune system (3). Sporozoite and liver stage 597 
antigens can be captured and presented by CD8a+ DCs in the spleen and/or the liver draining 598 
lymph nodes (DLN) for priming of naïve CD8+ T cells (4). Exposure of parasite antigens in 599 
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the liver leads to the differentiation of activated CD8+ T cells into tissue-resident memory T 600 
(Trm) cells that patrol the liver sinusoids (5). Aborted liver stage development prevents the 601 
appearance of an immunosuppressive blood stage infection (6). Upon reinfection or 602 
challenge, effector CD8+ T cells form clusters around infected hepatocytes and can eliminate 603 
parasites through direct killing of the infected cell and/or through the release of cytokines that 604 
inhibit parasite development (7). 605 
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